Aura Biosciences (NASDAQ:AURA) granted Nasdaq Rule 5635(c)(4) inducement equity awards to three newly hired executives effective September 1, 2026. Chief Regulatory and Quality Officer Erica Kratz, Ph.D., received stock options for 199,115 shares at an exercise price of $7.43 and 100,885 RSUs. Chief Operating Officer Susan Abu-Absi, Ph.D., received options for 265,487 shares at $7.43 and 134,513 RSUs. Chief People Officer Julie Person received options for 212,389 shares at $7.43 and 107,611 RSUs. Options vest 25% on the first service anniversary, then monthly over three years; RSUs vest in four annual 25% tranches starting September 15, 2027, subject to continued service. Aura is developing bel-sar, a first-in-class therapy for ocular cancers, with a fully enrolled Phase 3 study in early choroidal melanoma and additional earlier-stage studies ongoing.
Loading...
Loading translation...
Positive
None.
Negative
None.
News Explained
The September 1 grants are awards rather than an immediate common-share issuance, but their options and RSUs create potential future share issuance; if issued, the added shares would reduce existing holders’ percentage ownership.
Market Context
The announcement can be viewed alongside AURA's active S-3 shelf, which includes a $200,000,000 at-t...
Analysis
The announcement can be viewed alongside AURA's active S-3 shelf, which includes a $200,000,000 at-the-market program. Low short positioning and recent net selling provide additional context; future attention centers on award execution and capital use.
Key Figures
Kratz stock options:199,115 sharesKratz RSUs:100,885 sharesAbu-Absi stock options:265,487 shares+5 more
8 metrics
Kratz stock options199,115 sharesInducement Awards for Erica Kratz
Kratz RSUs100,885 sharesInducement Awards for Erica Kratz
Abu-Absi stock options265,487 sharesInducement Awards for Susan Abu-Absi
Abu-Absi RSUs134,513 sharesInducement Awards for Susan Abu-Absi
Person stock options212,389 sharesInducement Awards for Julie Person
Person RSUs107,611 sharesInducement Awards for Julie Person
Option exercise price$7.43 per shareEach executive's option awards
Initial option vesting25%On the first anniversary of the applicable executive's start date
Announced participation in two upcoming investor conferences.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Pattern Detected
AURA's historical reactions were positive after earnings and management news but negative after Phase 3 enrollment, showing mixed alignment with announcement sentiment.
"today announced that inducement equity awards (collectively, “Inducement Awards”) were granted"
Inducement equity awards are stock-based grants—such as shares or options—given to newly hired employees or executives as a hiring incentive, often issued outside a company’s standard long-term compensation plan. They matter to investors because they dilute existing ownership, create a charge against earnings, and align new hires’ pay with company performance; think of it as giving a slice of the pie upfront to convince someone to join, which changes each owner’s share and incentives.
non-qualified stock optionsfinancial
"non-qualified stock options to purchase an aggregate of 199,115 shares"
Non-qualified stock options are a type of employee benefit that gives individuals the right to buy company shares at a set price, usually lower than the market value, within a certain period. Unlike other options that may have special tax advantages, these options are taxed as income when exercised, which can affect how much money the employee or investor ultimately gains. They are important because they can influence company compensation strategies and impact the financial outcomes for employees and investors.
restricted stock unitsfinancial
"and restricted stock units (“RSUs”) for 100,885 shares of Common Stock"
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
nasdaq listing rule 5635(c)(4)regulatory
"in accordance with Nasdaq Listing Rule 5635(c)(4)"
NASDAQ Listing Rule 5635(c)(4) is a rule that requires a company to get approval from its shareholders before selling a large amount of its shares, usually over 20%. This helps protect investors by making sure the company doesn't flood the market with new shares without their say, which could lower the stock's value.
BOSTON, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Aura Biosciences, Inc. (NASDAQ: AURA) (“Aura” or the “Company”), a clinical-stage biotechnology company developing a potentially transformative first-in-class therapy for patients with ocular cancers, today announced that inducement equity awards (collectively, “Inducement Awards”) were granted to Erica Kratz, Ph.D., Aura’s new Chief Regulatory and Quality Officer, Susan Abu-Absi, Ph.D., Aura’s new Chief Operating Officer, and Julie Person, Aura’s new Chief People Officer, each on September 1, 2026 (the “Grant Date”). The Inducement Awards were approved by the Compensation Committee of the Board of Directors of the Company in accordance with Nasdaq Listing Rule 5635(c)(4).
The Inducement Awards granted to Dr. Kratz consist of (i) non-qualified stock options to purchase an aggregate of 199,115 shares of the Company’s common stock (“Common Stock”) with an exercise price of $7.43 per share, which is equal to the closing price of the Common Stock as reported by Nasdaq on the Grant Date and (ii) restricted stock units (“RSUs”) for 100,885 shares of Common Stock.The Inducement Awards granted to Dr. Abu-Absi consist of (i) non-qualified stock options to purchase an aggregate of 265,487 shares of Common Stock with an exercise price of $7.43 per share, which is equal to the closing price of the Common Stock as reported by Nasdaq on the Grant Date and (ii) RSUs for 134,513 shares of Common Stock.The Inducement Awards granted to Ms. Person consist of (i) non-qualified stock options to purchase an aggregate of 212,389 shares of Common Stock with an exercise price of $7.43 per share, which is equal to the closing price of the Common Stock as reported by Nasdaq on the Grant Date and (ii) RSUs for 107,611 shares of Common Stock.
Each of the option awards will vest as follows: 25% shall vest and become exercisable on the first anniversary of the applicable executive’s start date and the remaining 75% shall vest and become exercisable in 36 equal monthly installments thereafter, subject to such executive’s continued service as of each vesting date. The RSU awards will vest as follows: 25% shall vest on September 15, 2027 (the “First Vesting Date”), and 25% shall vest on each of the first year anniversary, second year anniversary, and third year anniversary of the First Vesting Date, subject to each executive’s continued service as of each vesting date.
AboutAura Biosciences
Aura Biosciences is a clinical-stage biotechnology company developing bel-sar, a potentially transformative, first-in-class therapy for patients living with ocular cancers. Bel-sar represents an entirely novel approach to treating ocular cancers via its dual mechanisms of action of acute tumor necrosis and secondary anti-tumor immune activation. The Phase 3 registration study of bel-sar in early choroidal melanoma, the largest patient segment of uveal melanoma, is fully enrolled, and earlier stage studies in metastases to the choroid and cancers of the ocular surface are ongoing. Aura's mission is to improve outcomes for patients living with ocular cancers by delivering a therapy that not only arrests tumor growth but also preserves vision and quality of life.
For more information, visit aurabiosciences.com. Follow us on X, @AuraBiosciences, and visit us on LinkedIn.
Investor and Media Relations Contact:
Alex Dasalla
Head of Investor Relations and Corporate Communications
What inducement equity awards did Aura Biosciences (NASDAQ:AURA) grant on September 1, 2026?
Aura Biosciences granted stock options and RSUs to three new executives as Nasdaq Rule 5635(c)(4) inducement awards. According to Aura Biosciences, the grants total several hundred thousand options and RSUs, structured to vest over four years, contingent on each executive’s continued service.
What are the share amounts and exercise price for the new AURA stock options granted to executives?
Aura Biosciences granted options for 199,115, 265,487, and 212,389 shares at an exercise price of $7.43 per share. According to Aura Biosciences, this price equals the Nasdaq closing price on the September 1, 2026 grant date and options vest over four years.
How do the RSU awards for Aura Biosciences (AURA) executives vest over time?
RSUs for the three Aura executives vest in four equal 25% annual installments starting September 15, 2027. According to Aura Biosciences, subsequent 25% tranches vest on the first, second, and third anniversaries of that date, subject to each executive’s continued service at every vesting point.
What is the vesting schedule for Aura Biosciences (AURA) inducement stock options?
Inducement options for Aura’s new executives vest 25% on the first anniversary of each executive’s start date. According to Aura Biosciences, the remaining 75% vests in 36 equal monthly installments thereafter, provided the executive continues in service on each scheduled vesting date.
Who received the Nasdaq Rule 5635(c)(4) inducement grants at Aura Biosciences (AURA)?
The inducement grants went to Erica Kratz, Ph.D., Chief Regulatory and Quality Officer, Susan Abu-Absi, Ph.D., Chief Operating Officer, and Julie Person, Chief People Officer. According to Aura Biosciences, each received a combination of non-qualified stock options and restricted stock units.
What is Aura Biosciences’ lead program bel-sar and what stage is it in?
Bel-sar is Aura Biosciences’ lead therapy candidate for ocular cancers, using dual mechanisms for tumor control and immune activation. According to Aura Biosciences, a Phase 3 registration study in early choroidal melanoma is fully enrolled, and earlier-stage studies in additional ocular indications are ongoing.
How might Aura Biosciences (AURA) inducement grants align executive incentives with shareholders?
The options and RSUs tie a portion of executive compensation to Aura’s share performance and long-term service. According to Aura Biosciences, vesting over four years encourages retention and potentially aligns leadership incentives with sustained value creation for existing AURA shareholders.
